Chemistry:Balcinrenone
From HandWiki
Short description: Pharmaceutical
 | |
| Clinical data | |
|---|---|
| Other names | AZD9977; AZD-9977 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H18FN3O5 |
| Molar mass | 399.378 g·mol−1 |
Balcinrenone is an experimental selective mineralocorticoid receptor modulator developed by AstraZeneca for heart failure. Compared to mineralocorticoid receptor antagonists, it is hoped to have less effect on electrolytes and therefore a lower risk of hyperkalemia.[1][2][3][4][5]
References
- ↑ Bamberg, Krister; Johansson, Ulrika; Edman, Karl; William-Olsson, Lena; Myhre, Susanna; Gunnarsson, Anders; Geschwindner, Stefan; Aagaard, Anna et al. (23 February 2018). "Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion". PLOS ONE 13 (2): e0193380. doi:10.1371/journal.pone.0193380. PMID 29474466. Bibcode: 2018PLoSO..1393380B.
- ↑ Bamberg, Krister; William-Olsson, Lena; Johansson, Ulrika; Jansson-Löfmark, Rasmus; Hartleib-Geschwindner, Judith (January 2019). "The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone". Journal of the Renin-Angiotensin-Aldosterone System 20 (1): 147032031982744. doi:10.1177/1470320319827449. PMID 30813831.
- ↑ Whittaker, Andrew; Kragh, Åsa M.; Hartleib-Geschwindner, Judith; Albayaty, Muna; Backlund, Anna; Greasley, Peter J.; Heijer, Maria; Kjaer, Magnus et al. (March 2020). "Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study". Clinical and Translational Science 13 (2): 275–283. doi:10.1111/cts.12705. PMID 31584739.
- ↑ Squire, Iain B.; Gabrielsen, Anders; Greasley, Peter J.; Wernevik, Linda; Hartleib-Geschwindner, Judith; Holden, Julie; Johansson, Susanne; Rudvik, Anna et al. (October 2022). "Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial". Clinical and Translational Science 15 (10): 2493–2504. doi:10.1111/cts.13377. PMID 35971596.
- ↑ Mallia, Carl J.; Le Bars, Joël; Hardy, Simon; Lamacraft, Alex; Harding, Simon; Hose, David; Snow, Lindsay; Poulten, Rebecca C. et al. (20 January 2023). "Control of Hydrogen Fluoride Formation and Release during a Large-Scale Nitroarene Reduction in the Manufacture of AZD9977". Organic Process Research & Development 27 (1): 167–178. doi:10.1021/acs.oprd.2c00323.
 |  |
